Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium.

People with neurofibromatosis type 1 (NF1) are at risk for developing peripheral nerve sheath tumors (PNSTs) ranging from benign neurofibromas to high-grade sarcomas. PNSTs known as atypical neurofibromas are at increased risk for malignant transformation. In 2017 the term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential) was proposed for PNSTs at increased risk for malignant transformation based on histopathologic features. Subsequently it was recognized that PNSTs not meeting ANNUBP criteria could still have concerning clinical, imaging and molecular features. A State of the Science conference addressed how to define these pre-cancerous PNSTs and reached consensus regarding clinical management and priority areas of research. Key recommendations from this symposium include: (1) using a combination of histologic, molecular and imaging features to define pre-malignant "at-risk" PNST; (2) recognizing that people with NF1 may be divided into "higher-risk" and "average-risk" for MPNST based on features such as their germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy and; (3) the need to validate consensus screening and surveillance strategies based on personal and tumor-related risk factors. These recommendations will advance the ability to standardize care, and potentially fuel research that enables early diagnosis, prevention of malignant transformation and improved outcomes.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/neuonc/noag275
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium.

Carol D. Morris, Benjamin I. Siegel, Dave Viskochil, Laura Marie Fayad et al.
3 links
PubMed
Neurofibromatosis and Schwannoma Cases
article

Defining and managing NF1-related peripheral nerve sheath tumors at risk for malignant transformation: Consensus from the Atypical Neurofibroma Symposium.

Carol D. Morris, Benjamin I. Siegel, Dave Viskochil, Laura Marie Fayad, Heike Elisabeth Daldrup-Link, Andrea M. Gross, Ina Ly, Lennart Well, Bruce R. Korf, Yin Wu, Angela C. Hirbe, Brian Weiss, Shivani Ahlawat, Inka Ristow, Miriam A. Bredella, K. Elizabeth Hawk, Rosalie E. Ferner, Jaishri O'Neill Blakeley, Eva Dombi, Kimberly K. Amrami, Brigitte C. Widemann, Carlos Guillermo Romo, Allan Joel Belzberg, Christine A. Pratilas, Fabian Mc. Johnston, Mark D. Murphey, Adam S. Levin, Prashant Chittiboina, Marcus Ratley, Michael J. Fisher, Steven Sheard, AeRang Kim
article en

Abstract

People with neurofibromatosis type 1 (NF1) are at risk for developing peripheral nerve sheath tumors (PNSTs) ranging from benign neurofibromas to high-grade sarcomas. PNSTs known as atypical neurofibromas are at increased risk for malignant transformation. In 2017 the term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential) was proposed for PNSTs at increased risk for malignant transformation based on histopathologic features. Subsequently it was recognized that PNSTs not meeting ANNUBP criteria could still have concerning clinical, imaging and molecular features. A State of the Science conference addressed how to define these pre-cancerous PNSTs and reached consensus regarding clinical management and priority areas of research. Key recommendations from this symposium include: (1) using a combination of histologic, molecular and imaging features to define pre-malignant "at-risk" PNST; (2) recognizing that people with NF1 may be divided into "higher-risk" and "average-risk" for MPNST based on features such as their germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy and; (3) the need to validate consensus screening and surveillance strategies based on personal and tumor-related risk factors. These recommendations will advance the ability to standardize care, and potentially fuel research that enables early diagnosis, prevention of malignant transformation and improved outcomes.

PubMed
Cincinnati Children's Hospital Medical Center (US), Guy's Hospital (GB), National Institutes of Health (US), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), Children's Hospital of Philadelphia (US), Children's National (US), Johns Hopkins University (US), Guy's and St Thomas' NHS Foundation Trust (GB), Washington University in St. Louis (US), University of Utah (US), Johns Hopkins Medicine (US), Riley Hospital for Children (US), University of Alabama at Birmingham (US), NYU Langone Health (US), Massachusetts General Hospital (US), Center for Neuro-Oncology (US), University Medical Center Hamburg-Eppendorf (DE), National Institute of Neurological Disorders and Stroke (US), Stanford Medicine (US), National Cancer Institute (US), Center for Cancer Research (US), Johns Hopkins Hospital (US), Indiana University School of Medicine (US), Wake Forest University Health Sciences (US), Wake Forest University (US), New York University (US), University of Cincinnati (US), University of Pennsylvania (US), Stanford University (US)
Good health and well-being
Neurofibromatosis and Schwannoma Cases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon